⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1533682 | 0.78 | — | — | |
| SCHEMBL4008375 | 0.76 | — | — | |
| SCHEMBL1198255 | 0.76 | — | — | |
| SCHEMBL5233601 | 0.76 | — | — | |
| SCHEMBL19718384 | 0.73 | — | — | |
| SCHEMBL15110978 | 0.73 | — | — | |
| SCHEMBL23498353 | 0.71 | — | — | |
| SCHEMBL6233700 | 0.71 | — | — | |
| SCHEMBL475767 | 0.71 | — | — | |
| SCHEMBL8708380 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103846-A1 | CYCLIC COMPOUND AND PREPARATION THEREFOR AND PHARMACEUTICAL USE THEREOF | 山东先声再明生物制药有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4558507-B1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| WO-2026041636-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2026-02-26 | — | — | WO | disclosed |
| EP-4688791-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4649081-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| EP-4146658-B1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PREC MEDICINE OPM (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4630424-A1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | Third Harmonic Bio, Inc. (US) | 2025-10-15 | — | — | EP | disclosed |
| US-20250268894-A1 | MACROCYCLE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2004046101-A2 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| CN-1134444-C | Epothilone analogs and pharmaceutical compositions thereof | 普罗格特-甘布尔公司 | 2004-01-14 | — | — | CN | disclosed |
| US-6660758-B1 | Prevention of mitosis; induction and stabilization of microtubules | THE SCRIPPS RESEARCH INSTITUTE | 2003-12-09 | — | — | US | disclosed |
| US-20030203938-A1 | Epothilone derivatives and their synthesis and use | THE SCRIPPS RESEARCH INSTITUTE | 2003-10-30 | — | — | US | disclosed |
| US-6441186-B1 | ANTICANCER AGENTS; PREVENTION OF MITOSIS THROUGH INDUCTION AND STABILIZATION OF MICROTUBULIN ASSEMBLY; SUPERIOR CYTOTOXIC ACTIVITIES | THE SCRIPPS RESEARCH INSTITUTE | 2002-08-27 | — | — | US | disclosed |
| EP-1089998-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | Novartis AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| CN-1246862-A | Epothilone analogs | NOVARTIS AG (CH) | 2000-03-08 | — | — | CN | disclosed |
| WO-1999067252-A2 | EPOTHILONE DERIVATIVES AND THEIR SYNTHESIS AND USE | NOVARTIS AG (CH) | 1999-12-29 | — | — | WO | disclosed |
| EP-0944634-A1 | EPOTHILONE ANALOGS | Novartis AG (CH) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998025929-A1 | EPOTHILONE ANALOGS | NOVARTIS AG (CH) | 1998-06-18 | — | — | WO | disclosed |